2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…2015 American Transplant Congress
Plasma 4β-Hydroxycholesterol Measurement as a Potential Biomarker for CYP3A5 Activity in Informing Tacrolimus Dosing
Background—Recently, 4β-hydroxycholesterol (4β-OHC) has been shown to be an endogenous marker of P450 3A activity in clinical practice (Diczfalusy et al, 2011). 4β-OHC concentration increases…2015 American Transplant Congress
Early Steroid Withdrawal and Calcineurin Inhibitor Minimization Protocols for Maintenance Immunosuppression: A Single Center 10-Year Experience
BACKGROUND:Long term use of steroids results in predictable secondary effects that can lead to increased morbidity and mortality. Additionally, long term high levels of Calcineurin…2015 American Transplant Congress
Calcineurin-Inhibitor Conversion to mTOR Inhibitor in Renal Transplant Recipients Leads to Worse Long Term Clinical Outcomes
We previously reported the short-term feasibility of Calcineurin-Inhibitor (CNI) elimination in kidney transplant recipients. We now report the long-term clinical impact on renal allograft function…2015 American Transplant Congress
Early Steroid Withdrawal and Infection Risk in Kidney Transplant Recipients
BACKGROUND: While early steroid withdrawal (ESW) is hypothesized to lower the risk of infection, previous studies failed to demonstrate this benefit. These were limited by…2015 American Transplant Congress
Steroid-Free Quadruple Induction Regimen With Basiliximab, Everolimus, Mycophenolate and Very Low Dose Tacrolimus Reduces Incidence of Biopsy-Proven Acute Rejection and Toxicity Profile Compared to the Standard Triple Regimen
Department of Renal Transplantation Surgery, Sapporo Hokuyu Hospital, Sapporo, Japan.
Objectives: Nephrotoxicity of calcineurin inhibitors (CNI) in kidney allografts has been a significant clinical problem even with low exposure regimens. On the other hand, CNI-free…2015 American Transplant Congress
Pharmacokinetics of Tacrolimus (TAC) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…2015 American Transplant Congress
Explorative Analysis of ZEUS After 5 Years: Histological Assessment from Biopsy Analyses
1ZEUS Study Group, Germany; 2Novartis, Pharma, Germany; 3ZEUS Study Group, Switzerland.
Background: Analysis of pathologists' assessments and histological data allow for deeper insight on patient outcome together with investigator's final clinical diagnoses. Here we present 5…2015 American Transplant Congress
Once-a-Day Administration of CNIs, mTOR and MMF Is Safe in De Novo Renal Transplant Recipients: 1-Year Results of a Pilot Study
Surgery - Renal Transplant Unit, Catholic University of the Sacred Heart, Rome, Italy.
Introduction. The half-lives of Tacrolimus, Everolimus, Cyclosporine and Mofetil Micofenolate (MMF) are respectively: 43, 30, 27 and 18 hours. Once-daily dosing of these drugs is…2015 American Transplant Congress
Comparison of Efficacy and Renal Function in KidneyTransplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination With Everolimus (EVR) or Mycophenolate (MPA)
1Nephrology, Hospital do Rim UNIFESP, Sao Paulo, Brazil; 2Pathology, UNIFESP, Sao Paulo, Brazil.
Introduction: Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with…
American Transplant Congress abstracts